Company profile
Edgewise Therapeutics, Inc.
NASDAQ:EWTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Sevasemten | phase1 | — | 3 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (17)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07795814 | phase2 | recruiting | 2026-08-25 | 2027-12-01 | Edgewise Therapeutics, Inc. | A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF) |
| NCT07177066 | phase1 | completed | 2025-08-20 | 2026-04-29 | Edgewise Therapeutics, Inc. | A Study of EDG-15400 in Healthy Adults |
| NCT05160415 | phase1 | completed | 2021-12-28 | 2024-03-01 | Edgewise Therapeutics, Inc. | A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy |
| NCT05540860 | phase2 | active_not_recruiting | 2022-10-24 | 2027-01-01 | Edgewise Therapeutics, Inc. | A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) |
| NCT06347159 | phase2 | active_not_recruiting | 2024-04-11 | 2027-12-01 | Edgewise Therapeutics, Inc. | A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM) |
FDA applications (0)
No records yet.